Prions and Neurodegenerative Diseases: Mechanisms of Protein Misfolding and Spread

Authors

  • Yichen Mi

DOI:

https://doi.org/10.61173/qfhv8j53

Keywords:

Prions, transmissible spongiform encepha-lopathies, neurodegeneration, protein misfolding, tau

Abstract

mwymwAbstract: Prion diseases, also known as transmissible spongiform encephalopathies, are universally lethal neurodegenerative disorders associated with the misfolding of the cellular prion protein into its pathological isoform. This arises through the ability of the misfolded protein to induce conformational changes in normally folded proteins, thereby initiating aggregation processes and neurodegenerative events. Very recent investigations have shown that such prion-like mechanisms are not limited to classic prion diseases but also play a role in the pathogenesis of neurodegenerative diseases (NDDs), including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Protein misfolding, aggregation, and the spreading of such proteins as amyloid-β, tau, and α-synuclein are related to the mechanisms of prion propagation, therefore accelerating disease. This review outlines the molecular pathways underlying prion misfolding, aggregation, and cell-to-cell transmission, focusing on state-of-the-art therapeutic strategies that interfere with these processes. Recent advancements in diagnostic techniques have, in particular, given great boosts to the presymptomatic diagnosis of prion diseases by means of the RT-QuIC assay. It concludes with a discussion of how further research into prion-like mechanisms may provide new therapeutic strategies for a wide array of NDDs.

References

[1] Horwich, A. L., Weissman, J. S. Deadly conformations-- protein misfolding in prion disease. Cell, 1997, 89(4): 499-510.

[2] Prusiner, S. B., et al. Prion protein biology. Cell, 1998, 93(3): 337-348.

[3] Van Everbroeck, B., et al. Transmissible spongiform encephalopathies: the story of a pathogenic protein. Peptides, 2002, 23(7): 1351-1359.

[4] Oesch, B., et al. Identification of cellular proteins binding to the scrapie prion protein. Biochemistry, 1990, 29(24): 5848- 5855.

[5] Scallet, A. C., Carp, R. I., Ye, X. Pathophysiology of transmissible spongiform encephalopathies. Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents, 2003, 3(2).

[6] DeArmond, S. J., Prusiner, S. B. Etiology and pathogenesis of prion diseases. The American Journal of Pathology, 1995, 146(4): 785-811.

[7] Joshi, T., Ahuja, N. The prion basis of progressive neurodegenerative disorders. Interdisciplinary Perspectives on Infectious Diseases, 2023.

[8] Caughey, B., Chesebro, B. Prion protein and the transmissible spongiform encephalopathies. Trends in Cell Biology, 1997, 7(2): 56-62.

[9] Hernaiz, A., Toivonen, J. M., Bolea, R., Martín-Burriel, I. Epigenetic changes in prion and prion-like neurodegenerative diseases: recent advances, potential as biomarkers, and future perspectives. International Journal of Molecular Sciences, 2022, 23(20): 12609.

[10] Jaunmuktane, Z., Brandner, S. Invited review: The role of prion-like mechanisms in neurodegenerative diseases. Neuropathology and Applied Neurobiology, 2020, 46(6).

[11] Song, Z., et al. Molecular mechanisms of neurodegeneration mediated by dysfunctional subcellular organelles in transmissible spongiform encephalopathies. Acta Biochimica et Biophysica Sinica, 2013, 45(6): 452-464.

[12] Kraus, A., et al. High-resolution structure and strain comparison of infectious mammalian prions. Molecular Cell, 2021, 81(21): 4540-4551.e6.

Downloads

Published

2025-06-26